Travere Therapeutics (TVTX)
(Delayed Data from NSDQ)
$16.41 USD
-0.70 (-4.09%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $16.40 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.41 USD
-0.70 (-4.09%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $16.40 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Zacks News
Travere (TVTX) Surges 11.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
Travere (TVTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Travere (TVTX) Soars 5.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Travere (TVTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Travere Gains 11% on Securing Full FDA Nod for Kidney Disease Drug
by Zacks Equity Research
The approval expands the label of TVTX's Filspari in IgAN indication. However, the label also comes with a boxed warning for liver problems and congenital disabilities.
Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Travere (TVTX) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Travere (TVTX) delivered earnings and revenue surprises of -3.45% and 9.33%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Travere (TVTX): Can Its 8.8% Jump Turn into More Strength?
by Zacks Equity Research
Travere (TVTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Travere (TVTX) Stock Jumps 5.2%: Will It Continue to Soar?
by Zacks Equity Research
Travere (TVTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Ligand (LGND) Beats Q1 Earnings, Misses Sales Estimates
by Zacks Equity Research
Ligand Pharmaceuticals (LGND) reports mixed first-quarter results. Management reiterates the 2024 financial outlook.
Here's What Key Metrics Tell Us About Travere (TVTX) Q1 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Travere (TVTX) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Travere (TVTX) delivered earnings and revenue surprises of -79.59% and 2.70%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Arcturus Therapeutics (ARCT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Travere (TVTX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Travere (TVTX) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Axsome (AXSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Travere (TVTX) Stock Up More Than 30% in 3 Months: Here's Why
by Zacks Equity Research
Travere (TVTX) is on track to file an sNDA to the FDA to convert the accelerated approval for lead drug, Filspari, to full approval for IgAN in first-quarter 2024.
Wall Street Analysts Think Travere (TVTX) Could Surge 66.29%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 66.3% upside potential for Travere (TVTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Mirum (MIRM) Down on Failure of Mid-Stage Study on Livmarli
by Zacks Equity Research
Mirum (MIRM) faces a setback in its efforts to expand its lead drug Livmarli's label for the indication of biliary atresia in patients who have undergone a Kasai surgery.
Travere (TVTX) Up on Latest Portfolio Updates & Reorganization
by Zacks Equity Research
Travere (TVTX) to submit an sNDA to the FDA to convert the accelerated approval for Filspari to full approval for IgAN in first-quarter 2024. The company is implementing a strategic reorganization to cut costs. Stock rises.
Travere (TVTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for Travere (TVTX) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Will Intercept Pharmaceuticals (ICPT) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Intercept (ICPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Travere Therapeutics (TVTX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Travere (TVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Travere (TVTX) Slumps 41% on Mixed Results From IgAN Drug Study
by Zacks Equity Research
Data from a confirmatory study shows that Travere's (TVTX) IgAN therapy did not achieve one of its confirmatory secondary endpoints. This will likely hurt the company's chances for the drug's full approval.
Xoma (XOMA) Moves 7.7% Higher: Will This Strength Last?
by Zacks Equity Research
Xoma (XOMA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Mirum Pharma (MIRM) Stock Rises 42% Year to Date: Here's Why
by Zacks Equity Research
Mirum Pharma (MIRM) surges 42% year to date due to encouraging progress in label-expansion efforts of Livmarli, along with strategic initiatives, to expand its commercial portfolio.
Travere (TVTX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Travere (TVTX) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Travere (TVTX) delivered earnings and revenue surprises of 2.59% and 10.70%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?